Table 4.
Study 10, Part 2A36 N=42 |
ARIEL 2, Part 124 N=204 |
Joint analysis (Study 10 and ARIEL 2)46 N=377 |
ARIEL 342 N=372 (rucaparib arm) |
|
---|---|---|---|---|
Discontinuation for AE (%) | 10 | 9 | 10 | 13 |
Dose reduction due to AE (%) | 69 | 39 | 46 | 55 |
At least one dose reduction or treatment delay (%) | 90 | nr | 62 | 88 |
Abbreviations: AE, adverse event; N, number of patients; nr, not reported; bid, twice a day.